PMS Registry
Company Name
Gilead Sciences Hong Kong Ltd. Taiwan Branch
Protocol Number
GS-TW-540-5928
Title of Study
A Post-Authorization Study to Evaluate Safety and Clinical Outcomes in COVID-19 Patients Treated with Veklury® (Remdesivir) in Taiwan
Primary Objective
The primary objective of this study is to assess the overall safety profile of Veklury in COVID-19 patients, including deaths.
Number of Sites
5
Period of Study
From:2021/08/03 to:2025/Q1
Number of Patients
100人
IRB Approval Date
National Taiwan University Hospital – 25May2021
Taoyuan General Hospital – 04Aug2021
Taichung Veterans General Hospital – 02Jun2021
Tri-Service General Hospital – 17Jun2021
Chang Gung Medication Foundation – Linkou Branch – 23Jun2021
Publication Plan / Date
No publication planned at this moment.